Here's the text of an email received today from the National ME/FM Action Network (Canada): "In December our CEO, Lydia Neilson sent a letter to Mr. Horton at the Lancet. Last week, she received a reply from Elizabeth Zuccala, Senior Editor of the Lancet. Below is a follow-up letter to Elizabeth Zuccala from Lydia Neilson. *** Ref. D-16-08953 Dear Ms Zuccala: Please understand that the letter sent to Mr. Horton on December 18, 2016 represent the opinions of the National ME/FM Action Network and that of the people suffering from Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS). Our organization is a National one for Canada but are in touch with people around the world who contact us, including the UK who have been avidly keeping up to date about what The Lancet is planning to do. This is an international dilemma where people for ME/CFS are being subjected to psychological therapies under the PACE study for a medical illness. Now that the facts have been exposed as to the actual data of the PACE study, it is important that The Lancet corrects its position on ME/CFS and amend the PACE study to reflect that fact. For your convenience, I am attaching a copy of our original letter to Editor, Richard Horton, of The Lancet. This is not about publishing or not publishing a letter, this is about putting people with ME/CFS in danger when treated with CBT/GET therapy. Unless and until the proper steps are taken by The Lancet to correct this useless and dangerous treatment for people with ME/CFS, we will continue to pursue any and all ways possible to have this travesty eliminated. The Lancet does not only owe this to the ME/CFS community but the credibility of The Lancet and scientists and researchers. If medical and scientific data cannot be depended upon as being accurate and scientific, then The Lancet becomes no longer a viable source for medical information. Sincerely, Lydia E. Neilson, MSM Founder and CEO NATIONAL ME/FM ACTION NETWORK Email from the Lancet On Friday, January 27, 2017 6:44 AM, The Lancet Peer Review Team <email@example.com> wrote: Manuscript reference number: THELANCET-D-16-08953 Title: Correspondence Dear Ms Neilson, Thank you for submitting your Letter to The Lancet. Having discussed your Letter with the Editor, and weighing it up against other submissions we have under consideration, I am sorry to say that we are unable to accept it at this time. Please be reassured that your Letter has been carefully read and discussed by the Editors. Thank you for your interest in The Lancet, I hope this decision does not deter you from considering us again in the future. Yours sincerely Elizabeth Zuccala Senior Editor" Bolded emphasis is mine.